Abstract: Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or glucose transporters. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, insulin resistance, chronic hyperinsulinemia, dysmetabolic syndrome, type A insulin resistance syndrome, type B insulin resistance syndrome, gestational diabetes, acanthosis nigricans, polycystic ovary syndrome (PCOS), obesity, muscle wasting, cardiovascular diseases, cardiac hypertrophy, myocardial ischemia, hypertension, pancreatic cancer associated diabetes (PCDM), rhabdomyosarcoma, or cancers.

Abstract: Disclosed herein are antibodies that specifically bind to LRIG1 and methods of use thereof. In some embodiments, also described herein are methods of modulating immune system activity or promoting immune cell proliferation with an antibody that specifically binds to LRIG1.

Abstract: This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.

Abstract: This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.

Abstract: This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.

Abstract: This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.